CALIPSO

Looking for Answers in a Warming World

Retrieved on: 
Wednesday, June 14, 2023
U.S. Department of Energy, Office of Inspector General, Science, Coral, Paris, Paris Agreement, Partnership, Silver iodide, Bismuth(III) iodide, Climate, U.S. Department of Defense Strategy for Operating in Cyberspace, City, Wildfire, Electricity, CCT, Environmental Research Letters, Research, Temperature, Burn, Carbon, Snow, Mitigation, Forecasting, CALIPSO, Sunlight, Running, NOAA, Climate change, Data analysis, Ice, DRI, Risk, Fresh water, Smoke, Water, Soot, Dust, Air conditioning, Physics, Architecture, Ethics, Weather, Growth, Mitchell, Society, Greenhouse, White, Commerce, U.S. Department of Commerce Office of Security, Agriculture, Renewable energy, Risk management, Arctic

Crossing this seemingly minor threshold could mean a world without coral reefs, a meter in sea-level rise, and frequent ice-less summers in the Arctic.

Key Points: 
  • Crossing this seemingly minor threshold could mean a world without coral reefs, a meter in sea-level rise, and frequent ice-less summers in the Arctic.
  • That’s the rationale for climate intervention research.”
    Mitchell is part of a team of DRI researchers examining the potential for climate intervention strategies to reduce global warming impacts.
  • Unlike other clouds, they have an overall warming effect on the climate, trapping thermal radiation near the surface that outweighs the solar radiation they reflect.
  • Cities across the world experience enhanced warming because of the way manmade surfaces, like asphalt, pavement, and buildings, absorb and radiate heat.

Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology

Retrieved on: 
Monday, November 22, 2021
Patient, European Medicines Agency, US Foods, Nephrology, Acquisition, Population, FDI, University, Disease, Peripheral artery disease, Pain, Pharma, Generalized arterial calcification of infancy, CUA, CALIPSO, EUR, University of the Balearic Islands, Calcification, Balearic Islands, Wound healing, Vifor Pharma, Chronic kidney disease, Mortality, Dialysis, PAD, Cardiovascular disease, Fine chemical, Pharmaceutical industry

Vifor Pharma will acquire Sanifit, for the continued development and commercialization of SNF472, a novel, first-in-class inhibitor of vascular calcification for the treatment of CUA and PAD in patients with end-stage kidney disease.

Key Points: 
  • Vifor Pharma will acquire Sanifit, for the continued development and commercialization of SNF472, a novel, first-in-class inhibitor of vascular calcification for the treatment of CUA and PAD in patients with end-stage kidney disease.
  • Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the outstanding shares in Sanifit Therapeutics, receiving full global rights for SNF472, further enhancing the companys portfolio of innovative assets.
  • Todays exciting announcement helps us to build on our strong nephrology pipeline to help end-stage kidney disease patients globally, commented Abbas Hussain, Chief Executive Officer of Vifor Pharma Group.
  • We are excited to join forces with Vifor Pharma, which has a world-renowned commitment to patient focused cardio-renal therapies.

Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology

Retrieved on: 
Monday, November 22, 2021
Patient, European Medicines Agency, US Foods, Nephrology, Acquisition, Population, FDI, University, Disease, Peripheral artery disease, Pain, Pharma, Generalized arterial calcification of infancy, CUA, CALIPSO, EUR, University of the Balearic Islands, Calcification, Balearic Islands, Wound healing, Vifor Pharma, Chronic kidney disease, Mortality, Dialysis, PAD, Cardiovascular disease, Fine chemical, Pharmaceutical industry

Vifor Pharma will acquire Sanifit, for the continued development and commercialization of SNF472, a novel, first-in-class inhibitor of vascular calcification for the treatment of CUA and PAD in patients with end-stage kidney disease.

Key Points: 
  • Vifor Pharma will acquire Sanifit, for the continued development and commercialization of SNF472, a novel, first-in-class inhibitor of vascular calcification for the treatment of CUA and PAD in patients with end-stage kidney disease.
  • Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the outstanding shares in Sanifit Therapeutics, receiving full global rights for SNF472, further enhancing the companys portfolio of innovative assets.
  • Todays exciting announcement helps us to build on our strong nephrology pipeline to help end-stage kidney disease patients globally, commented Abbas Hussain, Chief Executive Officer of Vifor Pharma Group.
  • We are excited to join forces with Vifor Pharma, which has a world-renowned commitment to patient focused cardio-renal therapies.

Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG

Retrieved on: 
Monday, November 22, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Patient, European Medicines Agency, US Foods, Nephrology, Acquisition, LR, Population, ART, FDI, University, Disease, Pain, Generalized arterial calcification of infancy, CUA, CALIPSO, EUR, University of the Balearic Islands, Calcification, CET, Balearic Islands, Wound healing, Foreign direct investment, CHF, Vifor Pharma, Lead, AVS, Chronic kidney disease, Mortality, Calcifying odontogenic cyst, Dialysis, PAD, Cardiovascular disease, CKD, Pharmaceutical industry, Vifor Pharma Group, SNF472, INS-3001, CUA, PAD, AVS, VIFOR PHARMA GROUP, SNF472, INS-3001, CUA, PAD, AVS

53 LR

Key Points: 
  • 53 LR
    Vifor Pharma has announced the acquisition of Sanifit Therapeutics, a Spanish clinical-stage cardio-renal biopharmaceutical company focused on treatments for end-stage kidney disease patients with progressive vascular calcification disorders, and Inositec AG, a Swiss company, developing first-in-class non-dialysis treatments for soft tissue and vascular calcification disorders.
  • Through these acquisitions, Vifor Pharma will be able to serve a continuum of vascular calcification disorders at all stages of CKD.
  • Acquisition of Sanifit is for the continued clinical development and commercialization of SNF472, a novel, first-in-class intravenously administered inhibitor of vascular calcification, for the treatment of CUA and PAD in patients with end-stage kidney disease.
  • Vifor Pharma will acquire 100% of the shares in Inositec AG, receiving full global rights for the lead asset INS-3001.

NASA, Partners Name Ocean Studying Satellite for Noted Earth Scientist

Retrieved on: 
Tuesday, January 28, 2020
Spaceflight, Spacecraft, Outer space, Earth orbits, Satellite imagery, CNES, Satellite, Sun-synchronous orbit, Earth observation satellite, Physical oceanography, Remote sensing, CALIPSO

WASHINGTON, Jan. 28, 2020 /PRNewswire/ --NASA and several partners announced Tuesday they have renamed a key ocean observation satellite launching this fall in honor of Earth scientist Michael Freilich, who retired last year as head of NASA's Earth Science division, a position he held since 2006.

Key Points: 
  • WASHINGTON, Jan. 28, 2020 /PRNewswire/ --NASA and several partners announced Tuesday they have renamed a key ocean observation satellite launching this fall in honor of Earth scientist Michael Freilich, who retired last year as head of NASA's Earth Science division, a position he held since 2006.
  • The Sentinel-6A/Jason CS satellite, scheduled to launch this fall from Vandenberg Air Force base in California, will now be known as Sentinel-6 Michael Freilich.
  • NASA and its partners are developing the mission with support from the Centre National d'Etudes Spatiales (CNES), France's space agency.
  • Unlike many of the traditional Earth observation platforms, the space station orbits Earth in an inclined equatorial orbit that is not sun-synchronous.

NASA, French Space Laser Measures Massive Migration of Ocean Animals

Retrieved on: 
Wednesday, November 27, 2019
Spacecraft, Spaceflight, CALIPSO, Environmental science, In France, Lidar, Calypso, Plankton, Aerosol, Cloud, ocean Ecosystem, Wide Field Camera

Researchers observed this vertical migration pattern using the Cloud-Aerosol Lidar and Infrared Pathfinder Satellite Observations (CALIPSO) satellite -- a joint venture between NASA and the French space agency, Centre National d'Etudes Spatiales -- that launched in 2006.

Key Points: 
  • Researchers observed this vertical migration pattern using the Cloud-Aerosol Lidar and Infrared Pathfinder Satellite Observations (CALIPSO) satellite -- a joint venture between NASA and the French space agency, Centre National d'Etudes Spatiales -- that launched in 2006.
  • "I think we are just scratching the surface of exciting new ocean science that can be accomplished with lidar."
  • Scientists recognize this natural daily movement around the world as the largest migration of animals on Earth in terms of total number.
  • NASA uses the vantage point of space to understand and explore our home planet, improve lives and safeguard our future.